Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ginsenoside-Rp1
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ginsenoside-Rp1** is a semi-synthesized derivative of ginsenoside Rg3, a saponin found in *Panax ginseng*. It is more stable and less toxic than Rg3 and exhibits strong anti-thrombotic, anti-inflammatory, and anti-tumor activities. Its mechanisms of action include inhibition of platelet activation (via the glycoprotein VI [GPVI] signaling pathway and suppression of ERK2 and p38 MAPK activation), attenuation of AKT and SIRT1 signaling implicated in multidrug resistance, and modulation of immune cell populations such as regulatory T cells (Tregs) and dendritic cells. Ginsenoside-Rp1 has demonstrated anti-metastatic and anti-inflammatory properties through NF-κB inhibition, and shows therapeutic potential for cardiovascular disorders, cancers (including colorectal and colon cancers), and inflammatory diseases[1][2][3][7][9][10][11].
- Other names
- ginsenoside-Rp1ginsenoside-Rp-1ginsenoside-Rp 1G-Rp1G-Rp-1G-Rp 1Rp1Rp-1Rp 1
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)FYN (Proto-oncogene tyrosine-protein kinase Fyn)GPVI (Platelet glycoprotein VI)LAT (Linker for activation of T cells)LYN (LYN proto-oncogene, Src family tyrosine kinase)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)PLCG2 (Phospholipase C gamma 2)PKA (Cyclic amp-dependent protein kinase)SYK (Spleen Tyrosine Kinase)RK (Ribokinase)AKT (RAC-alpha serine/threonine-protein kinase)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on ginsenoside-Rp1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ginsenoside-Rp1.